KATHLEEN DUNN: Open Payments
NPI 1073024238 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,496 in 98 payments from 17 companies in 2025. Trend: 2023 $964 · 2024 $950 · 2025 $1,496
Food & beverage: $1,451Education: $45
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $490 |
| Novo Nordisk Inc | 16 | $221 |
| Otsuka America Pharmaceutical, Inc. | 8 | $214 |
| PFIZER INC. | 12 | $194 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Lilly USA, LLC | 2 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $35 |
| Lundbeck LLC | 1 | $29 |
| Exact Sciences Corporation | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
Products named: VRAYLAR, REXULTI, Ozempic, NURTEC ODT, QULIPTA, UBRELVY, CAPLYTA, Wegovy.
Industry payments across IN — which companies pay providers there.
